2026 ICD-10-CM Diagnosis Code T44.1X6AUnderdosing of other parasympathomimetics [cholinergics], initial encounter

ICD-10-CM CodesS00–T88T36-T50T44

ICD-10-CM T44.1X6A
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T44.1X6A is a billable ICD-10-CM diagnosis code for underdosing of other parasympathomimetics [cholinergics], initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Underdosing of drugs and medicaments, initial encounter.

Code Identity

ICD-10-CM Code
T44.1X6A
Billable Status
Yes — Valid for Submission
Code Describes
Underdosing of other parasympathomimetics [cholinergics], initial encounter
Short Description
Underdosing of other parasympathomimetics, initial encounter
Parent Code
Underdosing of other parasympathomimetics [cholinergics]

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT44Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system
This CodeT44.1X6AUnderdosing of other parasympathomimetics [cholinergics], initial encounter

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T44.1X6A.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Coding GuidelinesGuidance

Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system (T44). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ029
Underdosing of drugs and medicaments, initial encounter
Default principal diagnosis: inpatient No · outpatient No

Clinical InformationClinical

  • Acetylcholine

    a neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system.
  • Acetylcholine Release Inhibitors

    compounds that block release of the neurotransmitter acetylcholine.
  • Acetylcholinesterase

    an enzyme that catalyzes the hydrolysis of acetylcholine to choline and acetate. in the cns, this enzyme plays a role in the function of peripheral neuromuscular junctions. ec 3.1.1.7.
  • Cholinergic Agents

    any drug used for its actions on cholinergic systems. included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons. the term cholinergic agents is sometimes still used in the narrower sense of muscarinic agonists, although most modern texts discourage that usage.
  • Cholinergic Agonists

    drugs that bind to and activate cholinergic receptors.
  • Cholinergic Antagonists

    drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
  • Cholinesterase Inhibitors

    drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.
  • Receptors, Cholinergic

    cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology.
  • Receptors, Muscarinic

    one of the two major classes of cholinergic receptors. muscarinic receptors were originally defined by their preference for muscarine over nicotine. there are several subtypes (usually m1, m2, m3....) that are characterized by their cellular actions, pharmacology, and molecular biology.
  • Receptors, Nicotinic

    one of the two major classes of cholinergic receptors. nicotinic receptors were originally distinguished by their preference for nicotine over muscarine. they are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors.
  • Vesicular Acetylcholine Transport Proteins

    vesicular amine transporter proteins that transport the neurotransmitter acetylcholine into small secretory vesicles. proteins of this family contain 12 transmembrane domains and exchange vesicular protons for cytoplasmic acetylcholine.
  • Arecoline

    an alkaloid obtained from the betel nut (areca catechu), fruit of a palm tree. it is an agonist at both muscarinic and nicotinic acetylcholine receptors. it is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. it has been used as a euphoriant in the pacific islands.
  • Bethanechol

    a slowly hydrolyzing muscarinic agonist with no nicotinic effects. bethanechol is generally used to increase smooth muscle tone, as in the gi tract following abdominal surgery or in urinary retention in the absence of obstruction. it may cause hypotension, heart rate changes, and bronchial spasm.
  • Bethanechol Compounds

    quaternary ammonium compounds that include bethanechol.
  • Carbachol

    a slowly hydrolyzed cholinergic agonist that acts at both muscarinic receptors and nicotinic receptors.
  • Pilocarpine

    a slowly hydrolyzed muscarinic agonist with no nicotinic effects. pilocarpine is used as a miotic and in the treatment of glaucoma.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
AceclidineT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
AcetylcholineT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Acetylcholine::chlorideT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Acetylcholine::derivativeT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
ArecolineT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Benzpyrinium bromideT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
BethanecholT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Bethanechol::chlorideT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
CarbacholT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Carbamylcholine chlorideT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Cholinergic (drug) NECT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Cholinergic (drug) NEC::muscle tone enhancerT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Cholinergic (drug) NEC::organophosphorusT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Cholinergic (drug) NEC::organophosphorus::insecticideT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Cholinergic (drug) NEC::organophosphorus::nerve gasT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Cholinergic (drug) NEC::trimethyl ammonium propanediolT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
MethacholineT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Parasympathomimetic drug NECT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
PilocarpineT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6
Pilocarpus (jaborandi) extractT44.1X1T44.1X2T44.1X3T44.1X4T44.1X5T44.1X6

Patient EducationClinical

Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T44.1X6A to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
No Map There is no ICD-9 equivalent for this code.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T44.1X6AOverview

Is T44.1X6A (Underdosing of other parasympathomimetics [cholinergics]) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report underdosing of other parasympathomimetics [cholinergics], initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character A in T44.1X6A mean?

The final character A marks the initial encounter: use it while the patient is receiving active treatment for underdosing of other parasympathomimetics [cholinergics], such as an emergency visit or first evaluation.

Can T44.1X6A be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because underdosing of other parasympathomimetics [cholinergics], initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.